Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world perioperative camrelizumab + apatinib study in resectable hepatocellular carcinoma
ChiCTR2600133384Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) and liver cancer, sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoints: Surgical safety and Medication treatment safety. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR2600133384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133384.